Bowen’s disease (squamous cell carcinoma in situ) - Dermatology Notes

Definition: An intraepidermal squamous cell carcinoma (SCC in situ) characterized by full-thickness epidermal atypia without invasion through the basement membrane. It is a precursor to invasive squamous cell carcinoma.

Key Clinical Features:

• Demographics: Older adults (sixth to seventh decade); slight female predominance.

• Morphology: Slowly enlarging, well-demarcated, erythematous to brownish plaque.

• Surface: Hyperkeratotic, scaly, or crusted; may be verrucous or psoriasiform.

• Size: Typically 1 to several centimeters; can become large.

• Border: Irregular but sharp.

• Classic sign: Scales and crusts are adherent; forceful removal reveals a moist, oozing, or eroded surface (no bleeding points – unlike invasive SCC).

• Locations: Sun-exposed areas (head, neck, dorsal hands, forearms, lower legs) – 80%. Also occurs on non-sun-exposed skin (trunk, perianal, genital – associated with HPV).

• Subungual or periungual Bowen’s disease: May present as longitudinal melanonychia or paronychia.

• Symptoms: Often asymptomatic; pruritus, burning, or tenderness in some.

Associated Conditions/Diseases:

• Chronic arsenic exposure: Bowenoid papulosis? No – arsenic causes multiple Bowen’s lesions (arsenical keratoses on palms/soles, Bowen’s on trunk, and internal malignancies).

• HPV (especially HPV 16, 18, 31, 34): Genital, perianal, and periungual Bowen’s – consider it as Bowenoid papulosis in young sexually active adults (histologically identical but clinically multiple small papules).

• Immunosuppression: Organ transplant recipients, HIV, lymphoma.

• UV radiation: Primary risk factor for sun-exposed sites.

• Internal malignancy: Controversial – classic teaching links Bowen’s to internal malignancy (especially arsenical Bowen’s), but modern studies show no significant association except in arsenic-exposed populations.

Prognosis:

• Excellent for life expectancy if treated.

• Risk of progression to invasive SCC: 3–5% (higher in genital/periungual sites, larger lesions, longer duration, immunosuppressed patients).

• Invasive transformation may occur after 10–20 years.

• Metastatic potential: Extremely low if treated before invasion. Once invasive, behaves like conventional SCC.

Differential Diagnosis:

• Psoriasis: Silvery-white scale, Auspitz sign, bilateral symmetric, other body sites involved.

• Actinic keratosis (AK): Thinner scale, erythema less intense, histology shows partial-thickness atypia (not full-thickness).

• Superficial basal cell carcinoma (BCC): Pearly border, telangiectasias, less scaly, histology shows basaloid cells with palisading.

• Nummular eczema: Spongiosis on histology, more acute, responds to topical steroids.

• Bowenoid papulosis: Multiple small papules in genital area of young adults; histology identical to Bowen’s but benign course.

• Paget disease (mammary or extramammary): Paget cells (CK7+, GCDFP-15+) on histology, not keratinocytes.

• Lichen planus: Violaceous, polygonal papules, Wickham striae, histology shows band-like lymphocytic infiltrate and saw-tooth rete ridges.

• Porokeratosis: Cornoid lamella on histology (stack of parakeratotic cells with absent granular layer).

Management with Rationale:

1. Standard treatments (destructive/excisional):

   • Surgical excision with 3–5 mm margins – gold standard; allows histologic confirmation of complete removal and excludes invasion.

   • Curettage and electrocautery – good for small lesions (≤2 cm) on non-hair-bearing, non-flexural skin.

   • Cryotherapy (liquid nitrogen, 2 freeze–thaw cycles) – good for small, thin lesions; lower cure rate for thick/hyperkeratotic lesions.

2. Topical therapies (for multiple lesions, large areas, or poor surgical candidates):

   • 5-Fluorouracil (5-FU) 5% cream – topical chemotherapy; causes inflammatory reaction; 80–90% cure rate; apply once to twice daily for 3–6 weeks.

   • Imiquimod 5% cream – immune response modifier (TLR7 agonist); 70–90% cure rate; apply 3–7 times per week for 12–16 weeks.

   • Rationale for topical: Avoids scarring, useful for large field cancerization.

3. Photodynamic therapy (PDT) – topical aminolevulinic acid followed by red or blue light; good for large or multiple lesions; high recurrence rate (20–30%).

4. Laser ablation (CO2 or Er:YAG) – for genital/periungual sites; no tissue for histology (risk of missing invasion).

5. Radiotherapy – for large lesions or poor surgical candidates (but risk of radiation-induced malignancy).

6. Observation – not recommended due to 3–5% progression risk.

Rationale for surgical excision: Provides complete histologic evaluation to rule out invasive SCC (which changes prognosis and management).

Histopathology

1. FOUNDATIONS (First Principles)

• Normal epidermis: Stratified squamous epithelium with orderly maturation from basal layer (cuboidal, single row) to spinous layer (polyhedral with desmosomes) to granular layer (flattened with keratohyalin granules) to stratum corneum (anuclear, compact).

• Basement membrane: Separates epidermis from dermis; intact in in situ lesions.

• Keratinocyte differentiation: Regulated by p53, NOTCH1, and other tumor suppressors.

• Normal mitotic activity: Confined to basal layer.

2. INITIATING EVENT

• UV radiation (most common): UVB-induced cyclobutane pyrimidine dimers and 8-oxoguanine lesions → mutations in p53 tumor suppressor gene (UV signature mutations – CC to TT transitions).

• HPV (especially high-risk types 16, 18): E6 and E7 proteins degrade p53 and retinoblastoma protein (pRb) → dysregulated cell cycle.

• Arsenic: Chronic exposure induces p53 mutations, oxidative stress, and DNA hypomethylation.

• Immunosuppression: Impaired immune surveillance allows outgrowth of p53-mutated keratinocyte clones.

3. PATHOGENESIS

• p53 mutation (or HPV E6-mediated degradation) → loss of cell cycle arrest and DNA repair.

• Dysregulated keratinocyte proliferation → clonal expansion of atypical keratinocytes.

• Loss of normal differentiation program → keratinocytes retain nuclear atypia throughout all epidermal layers.

• Abnormal adhesion and polarity → disorderly arrangement (loss of palisading basal layer).

• No invasion because basement membrane remains intact (intact type IV collagen and laminin).

• Progressive accumulation of additional mutations (RAS, NOTCH1, EGFR) may eventually lead to basement membrane degradation (matrix metalloproteinases) → invasive SCC.

Why full-thickness but not invasive? The basement membrane is a physical and biochemical barrier. In situ lesions produce matrix metalloproteinases but also upregulate tissue inhibitors of metalloproteinases (TIMPs), maintaining an intact lamina densa.

4. HISTOPATHOLOGY EXPLAINED

Low power:

• Full-thickness epidermal atypia (all layers are abnormal) – the defining feature.

• Sharply demarcated from adjacent normal epidermis (lateral margin is abrupt).

• Acanthosis (thickened epidermis) – irregular, often with broad, flattened rete ridges.

• Hyperkeratosis (thickened stratum corneum) – may be orthokeratotic or parakeratotic.

• Intact basement membrane (no dermal invasion).

High power – cytologic atypia:

• Keratinocytes are large, pleomorphic (variable size and shape).

• Hyperchromatic nuclei (darkly stained, coarse chromatin).

• Irregular nuclear contours (notched, folded, or angulated).

• Increased nuclear-to-cytoplasmic ratio.

• Prominent nucleoli (often multiple).

• Frequent and atypical mitotic figures (tri-polar, tetra-polar, or ring mitoses) – found above the basal layer (abnormal location).

• Dyskeratotic keratinocytes (prematurely apoptotic, with eosinophilic cytoplasm and pyknotic nuclei) – individual cell keratinization.

• Multinucleated keratinocytes (fusion of adjacent atypical cells).

• Loss of normal polarity – basal layer is no longer a single row of palisading cells; cells are crowded, disorganized, and extend into suprabasal layers.

Specific architectural features:

• Clumped cells (atypical keratinocytes in nests).

• Mitoses above the basal layer – key discriminator from actinic keratosis (where mitoses are confined to basal layer).

• Acantholysis (loss of intercellular bridges) – may occur, creating intraepidermal clefts (pseudoglands).

• Koilocytes (in HPV-related Bowen’s) – large, atypical keratinocytes with perinuclear halos and raisinoid nuclei.

Dermis:

• Superficial perivascular lymphohistiocytic infiltrate (often dense).

• Papillary dermal fibrosis (chronic change).

• Solar elastosis (in UV-induced cases).

• No dermal invasion – basement membrane is intact (confirmed by PAS stain or type IV collagen IHC).

Why this appearance:

• Full-thickness atypia represents complete failure of keratinocyte differentiation – all layers behave like basal cells.

• Pleomorphism and hyperchromasia reflect aneuploidy and genomic instability.

• Atypical mitoses above basal layer indicate that even suprabasal cells are cycling – never seen in normal skin or benign conditions.

• Dyskeratosis represents attempted (but abnormal) terminal differentiation or apoptosis.

5. NAMING LOGIC & TERMINOLOGY

• Bowen’s disease – Named after John T. Bowen (American dermatologist, 1912) who first described it as a “precancerous dermatosis.”

• Squamous cell carcinoma in situ – Reflects that malignant keratinocytes are confined to the epidermis (in situ = in its original place).

• Full-thickness atypia – Atypia involves all layers from basal to granular.

• Dyskeratosis – Abnormal, premature keratinization (dys = bad, keratosis = keratin formation).

• Clumped cells – Nests of atypical keratinocytes within the epidermis.

• Pagetoid Bowen’s – Variant where atypical cells spread in pagetoid fashion (single cells, not nests) – can mimic Paget disease or melanoma.

6. STAINING & MARKERS

H&E: Diagnostic as described above.

Special stains (rarely needed for classic Bowen’s):

• PAS (periodic acid–Schiff): Highlights intact basement membrane (thin pink line at dermo-epidermal junction). Loss of PAS-positive basement membrane suggests invasion.

• Colloidal iron (for mucin): Negative (differentiates from Paget disease, which is mucin-positive).

Immunohistochemistry (useful in difficult cases or pagetoid variant):

• p53: Strong, diffuse nuclear positivity in 80–90% (mutant p53 accumulates due to prolonged half-life).

• Ki-67 (MIB-1): High proliferative index; positive cells seen in all epidermal layers (not confined to basal layer).

• CK5/6: Positive (high molecular weight cytokeratin, normal in squamous epithelium).

• p63: Positive (nuclear transcription factor in basal keratinocytes; diffuse in Bowen’s).

• CK7: Negative (distinguishes from Paget disease, which is CK7+).

• CEA (carcinoembryonic antigen): Negative (distinguishes from extramammary Paget disease).

• CK20: Negative (distinguishes from pagetoid melanoma? No – melanoma is S100+, HMB45+, SOX10+).

• p16: Positive in HPV-related Bowen’s (strong, diffuse nuclear and cytoplasmic staining) – surrogate marker for high-risk HPV.

• E-cadherin: Reduced or aberrant expression (loss of cell adhesion).

• Type IV collagen: Linear staining at basement membrane (intact in situ; disrupted in invasion).

HPV testing: In situ hybridization or PCR for HPV DNA in genital/periungual cases.

Why p53 is useful: Normal skin has weak, scattered p53 staining (wild-type p53 has short half-life). Strong diffuse staining indicates p53 mutation (accumulated protein).

7. TEMPORAL EVOLUTION

• Early lesion (thin, erythematous macule): Subtle atypia confined to basal and lower spinous layers (may be indistinguishable from actinic keratosis). Mitoses still present above basal layer? In very early Bowen’s, the distinction from AK can be arbitrary.

• Established lesion (scaly plaque): Full-thickness atypia, hyperkeratosis, acanthosis, frequent mitoses, dyskeratosis.

• Late lesion (thick, verrucous plaque): Marked acanthosis, pseudocarcinomatous hyperplasia (mimics invasive SCC), but basement membrane intact. Increased risk of focal invasion.

• Transformation to invasive SCC: Focal breach of basement membrane (seen as irregular tongues of atypical keratinocytes extending into dermis, often with desmoplastic stromal reaction, inflammation, and single-cell invasion). This is called Bowen’s disease with microinvasion (invasion ≤1 mm).

8. PATTERN RECOGNITION & DIAGNOSTIC LOGIC

• Pattern: Full-thickness epidermal atypia with intact basement membrane + hyperkeratosis + acanthosis.

Diagnostic pathway:

• Full-thickness atypia + intact basement membrane + no dermal invasion → Bowen’s disease (SCC in situ) .

• Full-thickness atypia + basement membrane breach + dermal tumor islands → Invasive SCC.

• Partial-thickness atypia (basal and lower spinous only) + sparing of upper layers → Actinic keratosis.

• Full-thickness atypia + koilocytes + patient young + genital site → Bowenoid papulosis (clinical differentiation – multiple small papules vs. single plaque).

• Full-thickness atypia + pagetoid pattern (single atypical cells, not nests) + CK7+ → Paget disease (IHC required).

• Full-thickness atypia + pagetoid pattern + S100+ HMB45+ → Melanoma in situ.

• Full-thickness atypia + hypergranulosis + wedge-shaped hyperkeratosis + cornoid lamella → Porokeratosis.

Key discriminator from actinic keratosis (board favorite):

• Bowen’s disease: Atypia involves full thickness; mitoses present above basal layer.

• Actinic keratosis: Atypia confined to lower two-thirds; mitoses only in basal layer; overlying stratum corneum is orthokeratotic (not parakeratotic) – actually AK often has alternating ortho/parakeratosis; the key is the depth of atypia.

Key discriminator from invasive SCC: Intact basement membrane (PAS, type IV collagen) and absence of dermal tumor islands.

9. CLINICO-PATHOLOGICAL CORRELATION

• Erythematous plaque → Dermal perivascular lymphohistiocytic infiltrate and dilated vessels.

• Adherent scale/crust → Hyperkeratosis and parakeratosis with retained scale.

• Oozing surface after scale removal → Focal erosion or ulceration (but no invasion – erosion is epidermal loss, not dermal invasion).

• Slow growth (years) → Indolent biological behavior; intact basement membrane prevents rapid invasion.

• No induration (usually) → No desmoplastic stromal response (unlike invasive SCC, which induces fibrosis).

• Hyperkeratotic/verrucous surface → Marked acanthosis and hyperkeratosis.

• Genital/periungual lesions → HPV association (histology may show koilocytes).

• Risk of invasive SCC (3–5%) → Accumulation of additional genetic mutations over time eventually degrading basement membrane.

10. EXAM-FOCUSED INSIGHTS

• Full-thickness atypia is the histologic definition – If it’s not full-thickness, it’s not Bowen’s.

• Mitoses above the basal layer are a board hallmark – Never seen in normal skin or actinic keratosis.

• Bowen’s disease is SCC in situ – Use the terms interchangeably.

• Actinic keratosis vs. Bowen’s – Depth of atypia is the key: partial (AK) vs. full (Bowen’s). Some pathologists call severe AK “AK grade III” and Bowen’s as “SCC in situ” – be precise.

• Bowenoid papulosis – Histologically identical to Bowen’s but clinically benign; occurs in young adults, genital area, multiple small papules; often HPV 16 positive. Boards love this distinction.

• Risk of progression to invasive SCC is low (3–5%) but real – Do not observe; treat.

• Arsenical Bowen’s – Multiple lesions on sun-protected skin (trunk), associated with palmar/plantar arsenical keratoses, and risk of internal malignancies (lung, bladder, skin).

• p53 immunohistochemistry is not diagnostic but supportive – Strong diffuse staining suggests mutation; wild-type p53 is weak and scattered.

• Pagetoid Bowen’s – Can mimic Paget disease or melanoma; use CK7 (Paget+), S100 (melanoma+), CK5/6 (Bowen’s+) to differentiate.

• Do NOT confuse with superficial BCC – BCC shows basaloid cells with palisading and retraction artifact, not squamous atypia.

• Treatment – Surgical excision with margins is gold standard; topical 5-FU or imiquimod for multiple lesions or poor surgical candidates, but no histologic confirmation of clearance.

Must-Know Board Exam Questions & Answers

Q1: A 70-year-old man presents with a 2 cm, erythematous, scaly plaque on the dorsal hand that has been slowly enlarging over 5 years. Forceful removal of the scale reveals a moist, oozing surface. What is the most likely diagnosis?

A: Bowen’s disease (squamous cell carcinoma in situ).

Q2: What is the histopathological definition of Bowen’s disease?

A: Full-thickness epidermal atypia (squamous atypia involving all layers of the epidermis) with an intact basement membrane and no dermal invasion.

Q3: A biopsy of a scaly plaque shows full-thickness keratinocyte atypia, hyperchromatic nuclei, and atypical mitotic figures above the basal layer. The basement membrane is intact. What is the diagnosis?

A: Bowen’s disease (SCC in situ).

Q4: What is the single most important histologic feature that distinguishes Bowen’s disease from actinic keratosis?

A: Depth of atypia – Bowen’s shows full-thickness atypia (involves all epidermal layers), while actinic keratosis shows partial-thickness atypia (lower two-thirds only). Mitoses above the basal layer are seen in Bowen’s but not in AK.

Q5: A 30-year-old sexually active man presents with multiple small, violaceous, verrucous papules on the penile shaft. Biopsy shows full-thickness epidermal atypia with koilocytes. What is the diagnosis, and how does it differ from Bowen’s disease?

A: Bowenoid papulosis. Histologically identical to Bowen’s disease, but clinically it presents as multiple small papules in young adults, has a benign course (spontaneous regression possible), and is strongly associated with HPV 16.

Q6: What is the risk of progression from Bowen’s disease to invasive squamous cell carcinoma?

A: 3–5% (higher in genital, periungual, and large lesions, and in immunosuppressed patients).

Q7: What immunohistochemical stain confirms an intact basement membrane in Bowen’s disease?

A: Type IV collagen or PAS (periodic acid–Schiff) shows a linear band at the dermo-epidermal junction.

Q8: A biopsy shows full-thickness epidermal atypia with single pagetoid cells scattered throughout the epidermis. IHC shows CK5/6+, p63+, CK7–, S100–. What is the diagnosis?

A: Bowen’s disease (pagetoid variant). CK7 negativity excludes Paget disease; S100 negativity excludes melanoma.

Q9: What is the gold standard treatment for Bowen’s disease, and why?

A: Surgical excision with 3–5 mm margins. Rationale: Provides complete histologic evaluation to confirm negative margins and exclude invasive SCC.

Q10: A patient with multiple Bowen’s lesions on the trunk (sun-protected skin) also has hyperkeratotic papules on the palms and soles. What is the most likely underlying etiology?

A: Chronic arsenic exposure. Arsenical keratoses on palms/soles + Bowen’s on trunk = arsenic until proven otherwise. Screen for internal malignancies (lung, bladder).